Rapid Point of Care COVID Market is Projected to Hit USD 5.0 Billion by 2035, at a Exceptional CAGR 9.3%

WiseGuy Reports, Oct. 2025 (Press Release) – The Rapid Point of Care COVID Market Global Outlook:

Global Rapid Point of Care COVID Market Growth Analysis and Trends Report Product Type (Antigen Tests, Antibody Tests, Molecular Tests), By Sample Type (Nasal Swab, Throat Swab, Saliva), By End User (Hospitals, Diagnostic Laboratories, Home Care), By Distribution Channel (Online Pharmacy, Retail Pharmacy, Direct Sales) and By Regions - Global Industry Forecast 2025 to 2035

Rapid Point of Care COVID Market Overview

Rapid Point of Care COVID Market: Accelerating Diagnostic Innovation for a Resilient Healthcare Future

The Rapid Point of Care COVID Market continues to evolve as global health systems prioritize speed, accessibility, and accuracy in disease detection. Valued at USD 1.87 billion in 2024, the market is projected to grow to USD 2.05 billion in 2025 and reach USD 5.0 billion by 2035, reflecting a strong CAGR of 9.3% between 2025 and 2035. As healthcare transitions toward decentralized, patient-centric models, point-of-care diagnostics are reshaping the landscape of infectious disease management, particularly in post-pandemic healthcare preparedness.

Market Overview

The Rapid Point of Care COVID Market encompasses diagnostic technologies designed to deliver fast, reliable results at or near the site of patient care. These include antigen, molecular, and antibody-based assays developed for hospitals, clinics, workplaces, and home use. The surge in COVID-19 testing during 2020–2023 accelerated innovation across molecular diagnostics, microfluidics, and biosensor integration—technologies that now form the foundation for broader infectious disease testing.

By 2024, the market reached maturity in high-income regions but continues to expand in emerging economies due to growing healthcare infrastructure, government support, and a shift toward rapid diagnostic solutions. For B2B enterprises, the market offers strategic opportunities in manufacturing, digital integration, supply chain optimization, and new product innovation.

Request To Free Sample of This Strategic Report –

https://www.wiseguyreports.com/sample-request?id=736064

Key Market Dynamics

The Rapid Point of Care COVID Market is driven by a combination of technological, epidemiological, and policy-related factors shaping demand and innovation:

• Increased Demand for Rapid Testing: Ongoing viral mutations and seasonal outbreaks have maintained global testing requirements.
• Advancements in Testing Technology: Innovations in biosensors, isothermal amplification, and AI-assisted diagnostics are improving test accuracy and speed.
• Government Support and Funding: Public health agencies continue to fund mass screening and preparedness programs.
• Rising Prevalence of COVID Variants: The emergence of new variants necessitates continuous test adaptation and production scaling.
• Growing Focus on Decentralized Healthcare: Point-of-care and home testing are central to reducing hospital burden and ensuring early detection.

These dynamics underscore how the Rapid Point of Care COVID Market has evolved from emergency pandemic response to a sustainable segment within the global diagnostic ecosystem.

🛒 Buy Now Premium Research Report –

https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=736064

Market Segmentation

The Rapid Point of Care COVID Market is segmented by product type, sample type, end user, distribution channel, and region, enabling detailed insights for industry stakeholders.

• By Product Type:
• Antigen Tests: Dominate the market for quick and affordable detection; widely used in public testing and home diagnostics.
• Molecular Tests (PCR and Isothermal Amplification): Offer higher accuracy and are gaining traction for confirmatory and clinical testing.
• Antibody Tests: Used primarily for immunity surveillance and post-infection monitoring.
• By Sample Type:
• Nasal and Nasopharyngeal Swabs: Standard for high-sensitivity results.
• Saliva Samples: Growing in popularity due to non-invasive collection and ease of self-testing.
• Blood and Plasma: Used for antibody detection and serological assays.
• By End User:
• Hospitals and Clinics: Remain primary adopters for clinical-grade diagnostics.
• Home Care Settings: Rapidly growing segment with self-test kits driving adoption.
• Diagnostic Laboratories: Continue to utilize point-of-care devices for mass testing and screening programs.
• Corporate and Institutional Testing: Used for workforce screening in high-occupancy environments.
• By Distribution Channel:
• Retail Pharmacies and Drugstores: Key channel for home test kit distribution.
• E-commerce Platforms: Expanding reach in both developed and developing markets.
• Direct Hospital and Government Procurement: Large-scale purchases for healthcare and community testing programs.

Regional Insights

North America dominates the Rapid Point of Care COVID Market, driven by strong healthcare infrastructure, established diagnostic manufacturers, and regulatory approvals by the FDA and Health Canada. The United States continues to lead due to widespread adoption of self-testing and corporate testing programs.

Europe follows with robust growth in Germany, the UK, France, and Italy, supported by public health initiatives and technological innovation from leading diagnostic firms. The region’s focus on pandemic resilience and digital health integration has reinforced adoption of rapid testing technologies.

Asia-Pacific (APAC) is the fastest-growing region, fueled by population density, government investments in healthcare, and domestic production capabilities in China, India, and Japan. Increasing collaborations between global companies and local diagnostic firms are accelerating market expansion.

South America and MEA (Middle East and Africa) are emerging regions with growing adoption due to improved healthcare access, rising awareness, and expanding availability of affordable test kits.

Browse In-depth Market Research Report (Pages, Charts, Tables, Figures)

https://www.wiseguyreports.com/reports/rapid-point-of-care-covid-market

Competitive Landscape

The Rapid Point of Care COVID Market features a mix of global leaders and emerging biotechnology firms, all competing to enhance speed, accuracy, and affordability of testing solutions. Continuous product innovation, mergers, and government partnerships define the competitive dynamics.

Key Companies in the Rapid Point of Care COVID Market:

• BioRad Laboratories
• MedMira
• Quidel Corporation
• Hologic
• Thermo Fisher Scientific
• Cepheid
• BD (Becton Dickinson)
• Abbott Laboratories
• GenMark Diagnostics
• Mylab Discovery Solutions
• Gingko Bioworks
• LumiraDx
• Roche Diagnostics
• OncoOne
• Siemens Healthineers
• Singlera Genomics

Abbott Laboratories, Roche Diagnostics, and Quidel Corporation lead in global distribution networks, while LumiraDx and Mylab Discovery Solutions focus on portable, cost-efficient platforms for emerging markets. Thermo Fisher Scientific and Cepheid dominate molecular testing innovations with AI integration and advanced automation capabilities.

Key Market Opportunities

For B2B enterprises, the Rapid Point of Care COVID Market offers multiple strategic growth opportunities:

• Increased Demand for Home Testing: Rising consumer preference for convenience and autonomy.
• Expansion of Telehealth Services: Integration of test results with digital healthcare platforms for remote monitoring.
• Integration with Wearable Technology: Combining biosensors and mobile apps for continuous health tracking.
• Rising Need for Rapid Results: Critical for airports, workplaces, and event-based health verification.
• Growing Focus on Infectious Disease Management: Leveraging COVID-era infrastructure for broader disease testing.

These opportunities highlight the ongoing shift from pandemic response toward a sustainable rapid testing ecosystem.

Future Outlook

The Rapid Point of Care COVID Market is expected to evolve into a cornerstone of global infectious disease surveillance. Advancements in molecular diagnostics, AI-driven data analytics, and integration with digital health ecosystems will redefine rapid testing efficiency and accessibility. As manufacturers pivot toward multipathogen testing platforms, the market will expand beyond COVID-19 to encompass flu, RSV, and other respiratory infections.

Reasons To Buy The Rapid Point of Care COVID Market Report:

➼ In-depth analysis of the Rapid Point of Care COVID Market on the global and regional levels.

➼ Major changes in market dynamics and competitive landscape.

➼ Segmentation on the basis of type, application, geography, and others.

➼ Historical and future market research in terms of size, share growth, volume, and sales.

➼ Major changes and assessment in market dynamics and developments.

➼ Emerging key segments and regions

➼ Key business strategies by major market players and their key methods

Other Related Reports from Latest WiseGuy Reports:

Medical Maggots Market

Direct Primary Care Market

Colesevelam Market

Tissue Expansion Market

Female Fertility Test Market

Cephalosporin Antibiotics Market

Pilocarpine Market

Humanized Antibody Market

Physician Credentialing Services Market

Enalapril Market

About US:

Wise Guy Reports is pleased to introduce itself as a leading provider of insightful market research solutions that adapt to the ever-changing demands of businesses around the globe. We want our clients to have information that can be used to act upon their strategic initiatives. We, therefore, aim to be your trustworthy partner within dynamic business settings through excellence and innovation. By offering comprehensive market intelligence, our company enables corporate organizations to make informed choices, drive growth, and stay ahead in competitive markets